The price of an Indian pharmaceutical stock surged more than 13 percent from the previous closing price as the company’s financial results show a robust Net profit growth of 124 percent YOY and revenue growth of 90 percent.
Price action
Trident Lifeline Ltd with a market capitalization of Rs. 348 crores. trading at Rs 303, which is close to 10 percent higher than the previous day’s closing price of Rs 275.25. The company was up by 13.7 percent Intraday.
What Happened
Trident Lifeline Ltd, a company engaged in manufacturing and selling pharmaceutical products, has announced its results for the Financial year ‘25. Its Revenue grew by 90 percent YoY from Rs. 26 Crores in Q4FY24 to Rs. 49.6 Crores in Q4FY25, and it grew by 70 percent QoQ from Rs. 29.2 Crores in Q3FY25 to Rs. 49.6 Crores in Q4FY25.
Its Net Profit grew by 124 percent YoY from Rs. 2.83 Crores in Q4FY24 to Rs. 6.33 Crores in Q4FY25. The Net profits have grown by 43.5 percent QoQ from Rs. 4.41 Crores in Q3FY25 to Rs. 6.33 Crores in Q4FY25.
The company’s Earnings Before Interest, Depreciation, and Taxes (EBIDT) has also grown by 123 percent YOY from Rs 4.24 in Q4FY24 to Rs 9.45 in Q4FY25. Its EPS has also grown by 157 percent YOY from Rs. 2.46 in Q4FY24 to Rs. 6.31 in Q4FY25.
About the company
Trident Lifeline Ltd is engaged in manufacturing, selling, and marketing pharmaceutical products in the domestic as well as international markets. Its business operations span formulations under its brands, a loan licence model, and a contract manufacturing model. It is also engaged in the distribution of pharmaceutical products through a third-party distribution network.
Written by Likesh Babu S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
